EGFR over-expression and mutation have been demonstrated as an important factor for growth and progression of lung adenocarcinoma (Merrick et al., 2006), but treatment efficacies of EGFR TKIs are weak and limited due to TKIs-related toxicities or high risk in part of patients (Rosenthal et al., 2014). The gene discussed is EGFR; the disease is lung adenocarcinoma.